Acrobiosystems for English
icon_bulk_orderAchat groupé/Commande rapide
user
  1. Tableau de bord
  2. Mon profil
  3. Mon adresse
  4. Mes commandes
  5. Adhésion à Acro
Connexion Inscription
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
Il n'y a pas de produit dans le panier !
Mon panier|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > SLAMF7

SLAMF7

Brief Information

Name:SLAM family member 7
Target Synonym:CS1,UNQ576/PRO1138,SLAMF7,Novel Ly9,SLAM Family Member 7,Membrane Protein FOAP-12,CD2 Subset 1,Protein 19A,CRACC,CD2-Like Receptor Activating Cytotoxic Cells,CD2-Like Receptor-Activating Cytotoxic Cells,19A24 Protein,CD319,19A,CD319 Antigen,Novel LY9 (Lymphocyte Antigen 9) Like Protein
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
SL7-HP2H6 Human PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His TagStar Staining
SL7-HP2H6-structure
SL7-HP2H3 Human PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag (Site-specific conjugation)
SL7-HP2H3-structure
SL7-HF2H7 Human FITC-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag
SL7-HF2H7-structure
SL7-HF2H7-sds
SL7-R52H7 Rhesus macaque Rhesus macaque SLAMF7 / CRACC / CD319 Protein, His Tag (MALS verified)
SL7-R52H7-structure
SL7-R52H7-sds
SL7-M5252 Mouse Mouse SLAMF7 / CRACC / CD319 Protein, Mouse IgG2a Fc Tag, low endotoxin
SL7-M5252-structure
SL7-M5252-sds
SL7-H82E0 Human Biotinylated Human SLAMF7 / CRACC / CD319 Protein, Avitag™,His Tag (HPLC verified)
SL7-H82E0-structure
SL7-H82E0-sds
SL7-H82E0-hplc
SL7-H5256 Human Human SLAMF7 / CRACC / CD319 Protein, Fc Tag
SL7-H5256-structure
SL7-H5256-sds
SL7-H5225 Human Human SLAMF7 / CRACC / CD319 Protein, His Tag (HPLC verified)
SL7-H5225-structure
SL7-H5225-sds
SL7-H5225-hplc
ACRO Quality

Part of Bioactivity data

SL7-HP2H3-Cell-based assay
SLAMF7 FACS

1e6 of the anti-SLAMF7 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human SLAMF7, His Tag (Cat. No. SL7-HP2H3) and negative control protein respectively, PE signals was used to evaluate the binding activity (QC tested).

Protocol
SL7-HF2H7-Cell-based assay
SLAMF7 FACS

2e5 of Anti-SLAMF7 CAR-293 cells were stained with 100 μL of 10 μg/mL of FITC-Labeled Human SLAMF7, His Tag (Cat. No. SL7-HF2H7) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested)

Protocol
SL7-H5256-ELISA
SLAMF7 ELISA

Immobilized Human SLAMF7, Fc Tag (Cat. No. SL7-H5256) at 1 μg/mL (100 μL/well) can bind Anti-SLAMF7/CS1 Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).

Protocol
SL7-R52H7-MALS-HPLC
SLAMF7 MALS images

The purity of Rhesus macaque SLAMF7, His Tag (Cat. No. SL7-R52H7) is more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.

Synonym Name

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

Background

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Elotuzumab PDL-063; HuLuc-63; BMS-901608 Approved Abbvie Inc, Bristol-Myers Squibb Company Empliciti United States Multiple Myeloma Bristol-Myers Squibb Company 2015-11-30 Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Polycythemia Vera; Smoldering Multiple Myeloma; Leukemia, Plasma Cell; Multiple Myeloma; Primary Myelofibrosis; Lymphoma; Thrombocythemia, Essential Details
Elotuzumab PDL-063; HuLuc-63; BMS-901608 Approved Abbvie Inc, Bristol-Myers Squibb Company Empliciti United States Multiple Myeloma Bristol-Myers Squibb Company 2015-11-30 Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Polycythemia Vera; Smoldering Multiple Myeloma; Leukemia, Plasma Cell; Multiple Myeloma; Primary Myelofibrosis; Lymphoma; Thrombocythemia, Essential Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital) Phase 2 Clinical University Hospital Würzburg Multiple Myeloma Details
WS-CART-CS1 WS-CART-CS1 Phase 1 Clinical Washington University School Of Medicine, Paula C. & Rodger O. Riney Blood Cancer Research Multiple Myeloma Details
MB-104 MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CAR Phase 1 Clinical City Of Hope National Medical Center Stomach Neoplasms; Glioblastoma; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms Details
CS1 Targeted CAR T-cells (Yake Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) Clinical Wuhan BioRaid Biotechnology Co Ltd, Tongji Hospital Hematologic Neoplasms Details
SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital) Phase 2 Clinical University Hospital Würzburg Multiple Myeloma Details
WS-CART-CS1 WS-CART-CS1 Phase 1 Clinical Washington University School Of Medicine, Paula C. & Rodger O. Riney Blood Cancer Research Multiple Myeloma Details
MB-104 MB-104; MB-105; MB-104 CS1 CAR; MB-105 PSCA CAR Phase 1 Clinical City Of Hope National Medical Center Stomach Neoplasms; Glioblastoma; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Multiple Myeloma; Prostatic Neoplasms Details
CS1 Targeted CAR T-cells (Yake Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) Clinical Wuhan BioRaid Biotechnology Co Ltd, Tongji Hospital Hematologic Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us

Germany+49 800 0826645

United Kingdom+44 808 281 3436

Netherlands+31 800 0224992

Switzerland+41 800 040 012

France+33 800 90 78 85

Sweden+46 20 12 76 94

Denmark+45 80 83 07 62

Belgium+32 800 27 125

Email
E-Mail
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland
linkedin twitter facebook youtube

Laisser un message

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap